293 related articles for article (PubMed ID: 36804058)
1. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy.
Zhang D; Li AM; Hu G; Huang M; Yang F; Zhang L; Wellen KE; Xu X; Conn CS; Zou W; Kahn M; Rhoades SD; Weljie AM; Fuchs SY; Amankulor N; Yoshor D; Ye J; Koumenis C; Gong Y; Fan Y
Cell Metab; 2023 Mar; 35(3):517-534.e8. PubMed ID: 36804058
[TBL] [Abstract][Full Text] [Related]
2. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma.
Ma W; Wang Y; Zhang R; Yang F; Zhang D; Huang M; Zhang L; Dorsey JF; Binder ZA; O'Rourke DM; Fraietta JA; Gong Y; Fan Y
Nat Cancer; 2021 Jan; 2(1):83-97. PubMed ID: 35121889
[TBL] [Abstract][Full Text] [Related]
3. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
4. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
5. Serine-dependent redox homeostasis regulates glioblastoma cell survival.
Engel AL; Lorenz NI; Klann K; Münch C; Depner C; Steinbach JP; Ronellenfitsch MW; Luger AL
Br J Cancer; 2020 Apr; 122(9):1391-1398. PubMed ID: 32203214
[TBL] [Abstract][Full Text] [Related]
6. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
7. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma.
Xia L; Liu JY; Zheng ZZ; Chen YJ; Ding JC; Hu YH; Hu GS; Xia NS; Liu W
Mol Ther; 2021 Oct; 29(10):3011-3026. PubMed ID: 34058385
[TBL] [Abstract][Full Text] [Related]
8. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.
Cui J; Zhang Q; Song Q; Wang H; Dmitriev P; Sun MY; Cao X; Wang Y; Guo L; Indig IH; Rosenblum JS; Ji C; Cao D; Yang K; Gilbert MR; Yao Y; Zhuang Z
Neuro Oncol; 2019 Nov; 21(11):1436-1446. PubMed ID: 31276594
[TBL] [Abstract][Full Text] [Related]
9. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
11. Serine Synthesis via PHGDH Is Essential for Heme Production in Endothelial Cells.
Vandekeere S; Dubois C; Kalucka J; Sullivan MR; García-Caballero M; Goveia J; Chen R; Diehl FF; Bar-Lev L; Souffreau J; Pircher A; Kumar S; Vinckier S; Hirabayashi Y; Furuya S; Schoonjans L; Eelen G; Ghesquière B; Keshet E; Li X; Vander Heiden MG; Dewerchin M; Carmeliet P
Cell Metab; 2018 Oct; 28(4):573-587.e13. PubMed ID: 30017355
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
13. Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells.
Sharif T; Martell E; Dai C; Ghassemi-Rad MS; Lee K; Singh SK; Weaver ICG; Gujar S
Cell Death Dis; 2018 Sep; 9(10):990. PubMed ID: 30250195
[TBL] [Abstract][Full Text] [Related]
14. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
Dong X; Ren J; Amoozgar Z; Lee S; Datta M; Roberge S; Duquette M; Fukumura D; Jain RK
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898734
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
Choi BD; Maus MV; June CH; Sampson JH
Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
Feldman L; Brown C; Badie B
Neuromolecular Med; 2022 Mar; 24(1):35-40. PubMed ID: 34665390
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
19. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model.
Murty S; Haile ST; Beinat C; Aalipour A; Alam IS; Murty T; Shaffer TM; Patel CB; Graves EE; Mackall CL; Gambhir SS
Oncoimmunology; 2020 May; 9(1):1757360. PubMed ID: 32923113
[TBL] [Abstract][Full Text] [Related]
20. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
Song Y; Liu Q; Zuo T; Wei G; Jiao S
Cell Immunol; 2020 Jun; 352():104112. PubMed ID: 32305131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]